Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

GlobeNewswire September 9, 2024

Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

GlobeNewswire August 27, 2024

Medicenna Strengthens Board of Directors with Appointment of Karim Lalji

GlobeNewswire August 15, 2024

Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy

GlobeNewswire August 1, 2024

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

GlobeNewswire June 27, 2024

Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe

GlobeNewswire June 26, 2024

Medicenna reveals positive results from brain cancer study

Jocelyn Aspa June 3, 2024

Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting

GlobeNewswire June 3, 2024

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

GlobeNewswire May 31, 2024

Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum

GlobeNewswire May 22, 2024

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting

GlobeNewswire May 13, 2024

Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

GlobeNewswire April 30, 2024

Canadian Investment Regulatory Organization Trade Resumption - MDNA

Canada NewsWire April 26, 2024

Canadian Investment Regulatory Organization Trading Halt - MDNA

Canada NewsWire April 26, 2024

Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management

GlobeNewswire April 26, 2024

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

GlobeNewswire April 24, 2024

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire April 10, 2024

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire April 9, 2024

Medicenna shares preclinical data on treatment targeting tumours

Jocelyn Aspa April 9, 2024